CPRX - Catalyst Pharmaceuticals Inc.: Stay The Course
Catalyst Pharmaceuticals ([[CPRX]]) reported very strong financial results for 2019’s second quarter, reporting 60% upside to the analyst consensus revenue estimate, also driving the company into profitable territory. We were a bit surprised with the muted reaction to the earnings print, however CPRX was up roughly 25% since mid-July in anticipation of potentially positive 2Q results.
Despite the run-up into earnings, we still see significant long-term upside from here, and also expect short-term follow-through on the positive quarterly results as investors digest the highly positive results and their implications for long-term value. In addition,